.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Type 2 diabetes (T2D) remains a significant health concern globally, especially within the Indian population. Because the disease prevalence is rising, clinicians are focusing on therapies that address both insulin resistance and impaired secretion. Incretin-based therapies, including glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have emerged as vital tools. These medications not only regulate glucose but also offer remarkable benefits for weight management. Consequently, they are now central to modern diabetes care strategies.
Modern research highlights that these agents offer more than just glycemic control. Additionally, they provide significant cardiovascular protection and facilitate substantial weight reduction. While the first GLP-1 receptor agonist was approved in 2005, the field has evolved rapidly. Today, clinicians can prescribe once-weekly injectables or daily oral formulations. Furthermore, dual agonists that target both GLP-1 and GIP receptors demonstrate superior metabolic outcomes compared to older treatments. As a result, patients at high cardiovascular risk can achieve better long-term health outcomes.
Despite their efficacy, these therapies frequently cause gastrointestinal side effects such as nausea or constipation. However, doctors can easily mitigate these issues through slow dose titration and comprehensive patient counseling. Encouraging smaller meals and proper hydration also helps improve patient adherence. Meanwhile, ongoing trials into triple-receptor agonists suggest even greater weight-loss potential in the future. Nevertheless, ensuring wider access to these advanced treatments remains a priority for healthcare systems.
Dual agonists provide enhanced glycemic control and more significant weight loss than single GLP-1 receptor agonists by utilizing synergistic hormonal pathways.
Gradual dose escalation over several weeks is the most effective strategy. Clinicians should also advise patients to eat smaller portions and avoid high-fat foods during drug initiation.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Min E et al. Incretins for Type 2 Diabetes. Can J Physiol Pharmacol. 2026 Jun 06. doi: 10.1139/cjpp-2025-0142. PMID: 42250284.
Gao X et al. Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes. PubMed. 2026 Mar 23. doi: 10.1111/jdi.14231.
Refaeli R et al. Gastrointestinal side effects of incretin-based Obesity Management Medications. Int J Obes. 2025 Aug 28. doi: 10.1038/s41366-025-01887-2.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Discover how GLP-1 and GIP agonists transform T2D management by improving glycemia, aiding weight loss, and lowering cardiovascular risks....
last month
Union Health Minister J P Nadda reported significant progress in tuberculosis control in India, with incidence dropping by 21% and mortality falling by 25% between 2015 and 2024. Furthermore, national screening initiatives for diabetes and common cancers have expanded clinical access across district-level facilities.
Today
A systematic review involving over 31,000 opioid-exposed children across 10 countries reveals that in utero exposure is linked to long-term visual impairment, attention deficits, and academic difficulties. Clinicians emphasize early developmental screening and family-centered support across health and education.
Yesterday
A JAMA study using Global Burden of Disease 2023 data reveals high LDL cholesterol caused 3.6 million deaths globally, with India and China bearing one-third of the disease burden. Addressing systemic barriers to statin therapy and strengthening primary care lipid screening remain critical clinical priorities.
4 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
Last week
New research indicates that weight regain after dieting is largely driven by evolutionary brain biology and neuroendocrine defenses rather than a lack of willpower. Understanding these central mechanisms helps clinicians optimize chronic obesity care.
Today
